A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

This publication has 29 references indexed in Scilit:

• Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children
  Human Vaccines & Immunotherapeutics, 2013
• The global distribution and burden of dengue
  Nature, 2013
• Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection
  Archives of Virology, 2013
• A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial
  Vaccine, 2012
• Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever
  Vaccine, 2011
• Dengue: a continuing global threat
  Nature Reviews Microbiology, 2010
• Does the Concurrent Administration of an Inactivated Hepatitis A Vaccine Influence the Immune Response to Other Travelers Vaccines?
  Journal of Travel Medicine, 2006
• Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide
  Travel Medicine and Infectious Disease, 2003
• Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development
  Journal of Virology, 2003
• Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults
  Vaccine, 1996